|
000
| 01575nam##2200301za#4500 |
|---|
| 001 | 9.644543 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20200515103500 |
|---|
| 007 | ta |
|---|
| 008 | 150407|1992||||xxc||||| f|0| 0 eng|d |
|---|
| 020 | |a0-660-14437-9 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aEC22-183/1992E |
|---|
| 110 | 2 |aEconomic Council of Canada. |
|---|
| 245 | 10|aControlling drug expenditure in Canada: the Ontario experience / |cby Paul K. Gorecki. |
|---|
| 260 | |aOttawa - Ontario : |bEconomic Council of Canada |c1992. |
|---|
| 300 | |a160p. : |bgraphs, tables ; |c28 cm. |
|---|
| 504 | |aBibliography. |
|---|
| 520 | 3 |aWhat factors influence the cost of health care in Canada? Initiated as a background study for the Pharmaceutical Inquiry of Ontario, this paper raises a broad range of drug management issues, from the merits of alternative forms of user fees to the virtues of different drug-pricing systems. The report also looks at the forces that shape provincial drug programs, and discusses the behaviour and motivation of pharmacists, physicians, manufacturers of generic and brand-name drugs, and consumers. Provides insightful background on the effective management and delivery of health care services in times of fiscal restraint. |
|---|
| 563 | |aSoftcover |
|---|
| 590 | |a92-27|b1992-07-03 |
|---|
| 690 | 07|aDrugs|2gcpds |
|---|
| 690 | 07|aCosts|2gcpds |
|---|
| 720 | 1 |aGorecki, Paul K. |
|---|
| 775 | 08|tLe contrôle des coûts de médicaments au Canada: le cas de l'Ontario / |w(CaOODSP)9.678374 |
|---|
| 776 | 0#|tControlling drug expenditure in Canada : |w(CaOODSP)9.868973 |
|---|